A detailed history of Captrust Financial Advisors transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 9,130 shares of REGN stock, worth $6.52 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,130
Previous 8,834 3.35%
Holding current value
$6.52 Million
Previous $9.28 Million 3.37%
% of portfolio
0.03%
Previous 0.03%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $303,130 - $355,720
296 Added 3.35%
9,130 $9.6 Million
Q2 2024

Aug 14, 2024

SELL
$883.2 - $1071.19 $57,408 - $69,627
-65 Reduced 0.73%
8,834 $9.28 Million
Q1 2024

May 15, 2024

SELL
$902.69 - $993.35 $3.29 Million - $3.62 Million
-3,645 Reduced 29.06%
8,899 $8.57 Million
Q4 2023

Feb 14, 2024

BUY
$775.18 - $881.7 $64,339 - $73,181
83 Added 0.67%
12,544 $11 Million
Q3 2023

Nov 14, 2023

BUY
$692.45 - $844.37 $267,978 - $326,771
387 Added 3.21%
12,461 $10.3 Million
Q2 2023

Aug 14, 2023

SELL
$700.03 - $830.35 $229,609 - $272,354
-328 Reduced 2.64%
12,074 $8.68 Million
Q1 2023

May 15, 2023

SELL
$680.49 - $826.97 $184,412 - $224,108
-271 Reduced 2.14%
12,402 $10.2 Million
Q4 2022

Feb 15, 2023

BUY
$705.89 - $766.39 $849,891 - $922,733
1,204 Added 10.5%
12,673 $9.14 Million
Q3 2022

Nov 16, 2022

BUY
$573.97 - $724.32 $471,803 - $595,391
822 Added 7.72%
11,469 $7.9 Million
Q2 2022

Aug 23, 2022

SELL
$548.35 - $738.84 $695,856 - $937,587
-1,269 Reduced 10.65%
10,647 $6.29 Million
Q2 2022

Aug 16, 2022

BUY
$548.35 - $738.84 $1.35 Million - $1.82 Million
2,458 Added 25.99%
11,916 $7.04 Million
Q1 2022

May 16, 2022

SELL
$595.12 - $698.43 $265,423 - $311,499
-446 Reduced 4.5%
9,458 $6.61 Million
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $1.83 Million - $2.26 Million
3,375 Added 51.69%
9,904 $6.26 Million
Q3 2021

Nov 16, 2021

BUY
$574.03 - $680.96 $2.66 Million - $3.16 Million
4,636 Added 244.9%
6,529 $3.95 Million
Q2 2021

Aug 16, 2021

BUY
$472.8 - $558.54 $1,891 - $2,234
4 Added 0.21%
1,893 $1.06 Million
Q1 2021

May 17, 2021

BUY
$446.73 - $548.2 $13,401 - $16,446
30 Added 1.61%
1,889 $894,000
Q4 2020

Feb 16, 2021

SELL
$478.3 - $607.98 $124,836 - $158,682
-261 Reduced 12.31%
1,859 $898,000
Q3 2020

Nov 17, 2020

BUY
$544.75 - $658.21 $235,332 - $284,346
432 Added 25.59%
2,120 $1.2 Million
Q2 2020

Aug 14, 2020

BUY
$493.32 - $643.92 $94,717 - $123,632
192 Added 12.83%
1,688 $1.03 Million
Q1 2020

May 15, 2020

BUY
$336.18 - $494.43 $255,832 - $376,261
761 Added 103.54%
1,496 $743,000
Q4 2019

Feb 14, 2020

BUY
$274.13 - $376.51 $144,466 - $198,420
527 Added 253.37%
735 $274,000
Q3 2019

Nov 14, 2019

BUY
$273.46 - $318.39 $34,455 - $40,117
126 Added 153.66%
208 $58,000
Q2 2019

Aug 13, 2019

BUY
$299.6 - $414.82 $7,490 - $10,370
25 Added 43.86%
82 $26,000
Q1 2019

May 15, 2019

SELL
$372.08 - $439.57 $8,557 - $10,110
-23 Reduced 28.75%
57 $23,000
Q4 2018

Feb 13, 2019

BUY
$335.82 - $403.04 $26,865 - $32,243
80 New
80 $30,000
Q1 2018

May 15, 2018

SELL
$315.82 - $393.78 $1,579 - $1,968
-5 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$358.63 - $469.95 $1,793 - $2,349
5
5 $2,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.